

L3                   E ETHANOL/CN  
                   1 S E15  
                   E DIAZEPAM/CN  
 L4                   1 S E27  
                   E HYDROCORTISONE/CN  
 L5                   1 S E39  
                   E CYCLOPHOSPHAMIDE/CN  
 L6                   1 S E51  
                   E PHENAZEPAM/CN  
 L7                   1 S E63

FILE 'CAPLUS' ENTERED AT 17:04:18 ON 29 JUL 2010

L8           355944 S L3-L7  
 L9           3876 S L8 AND (?HOMEOPATH? OR POTENTIAT? OR POTENTISAT?)  
 L10          3313 S L9 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
 L11          1979 S L3 AND (?HOMEOPATH? OR POTENTIAT? OR POTENTISAT?)  
 L12          69 S L3 AND (?HOMEOPATH?)  
 L13          43 S L12 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L13 ANSWER 17 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN  
 AB    The title method comprises (1) diluting any liqs. (excluding  
       alcs.) in an alc. solution, (2) shaking the resulting solns., (3)  
       repeating the steps of diluting and shaking multiple times, and  
       (4) impregnating the product into a solid saccharide.

ACCESSION NUMBER:       2001:573236 CAPLUS Full-text  
 DOCUMENT NUMBER:       135:142267  
 TITLE:                 Simple method for the manufacture of  
                        homeopathic drug delivery systems  
 INVENTOR(S):           Yui, Tomoko  
 PATENT ASSIGNEE(S):     Japan  
 SOURCE:                Jpn. Kokai Tokkyo Koho, 4 pp.  
                        CODEN: JKXXAF  
 DOCUMENT TYPE:         Patent  
 LANGUAGE:              Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----
JP 2001213790	A	20010807	JP 2000-23936	
20000201 <--				
PRIORITY APPLN. INFO.:			JP 2000-23936	
20000201 <--				
IPCI A61K0035-20 [ICM,7]; A61K0033-00 [ICS,7]; A61P0017-00 [ICS,7]; A61P0043-00 [ICS,7]				
IPCR A61K0033-00 [I,C*]; A61K0033-00 [I,A]; A61K0035-20 [I,C*]; A61K0035-20 [I,A]; A61P0017-00 [I,C*]; A61P0017-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]				
CC 63-6 (Pharmaceuticals)				
ST alc diln shaking homeopathic drug delivery				
IT Agitation (mechanical)				
Dilution				
(alc. dilution and shaking for preparation of homeopathic drug delivery systems for bioactive liqs.)				

IT Alcohols, biological studies  
 Polysaccharides, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alc. dilution and shaking for preparation of homeopathic drug  
 delivery systems for bioactive liqs.)

IT Drug delivery systems  
 (homeopathic; alc. dilution and shaking for preparation of  
 homeopathic drug delivery systems for bioactive liqs.)

IT 64-17-5, Ethanol, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alc. dilution and shaking for preparation of homeopathic drug  
 delivery systems for bioactive liqs.)

L13 ANSWER 28 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

AB Carrier solvents in pharmaceuticals should be excipient. Ethanol  
 in liquid preps. intended for children is an industry decision  
 but it is a metabolically active substrate, sometimes found in  
 subtherapeutic or subtoxic doses. Worst offenders in this respect  
 are prescription drugs for long-term treatment which inevitably  
 subject patients to chronic passive exposure. One hundred three  
 such preps. were identified from the Italian pharmacopoeia with  
 more than 20 mg/dL ethanol. OTCs and homeopathic remedies were  
 also found to contain large amts. (up to 60% volume) of ethanol  
 with even less clin. need or benefit. Domestic sources other than  
 medicinals were found to account for negligible amts. (>2 mg/dL).  
 Hepatic and extrahepatic enzyme route switching, hepatic blood  
 flow and plasma clearance are all age-dependent and the growth  
 process itself is increasingly thought to impact on drug  
 pharmacokinesis. The implications for pediatric prescribers are  
 that trademarks for the same active ingredient should be  
 differentially assessed against expected length of treatment and  
 ethanol amts., preferring non-alc. alternatives whenever possible.  
 Yet the medical literature has paradoxically ignored the need for  
 a toxicol. re-assessment of ethanol in children medications and  
 acceptable risk thresholds have not been determined

ACCESSION NUMBER: 1999:204080 CAPLUS Full-text

DOCUMENT NUMBER: 130:333988

TITLE: Ethanol in medicines and other products  
 intended for

children: commentary on a medical paradox  
 AUTHOR(S): Fiocchi, A.; Riva, E.; Giovannini, M.  
 CORPORATE SOURCE: Department of Paediatrics of the University of  
 Milan

Medical School at the San Paolo Biomedical  
 Institute,  
 Milan, 20142, Italy

SOURCE: Nutrition Research (New York) (1999), 19(3),  
 373-379

CODEN: NTRSDC; ISSN: 0271-5317

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

CC 4-7 (Toxicology)

IT 64-17-5, Ethanol, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (ethanol in medicines and other products intended for  
 children-commentary on medical paradox)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L13 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

AB A method of therapy for drug addiction is claimed. Potentiated morphine, prepared by repeated and successive dilution and agitation of morphine solution or a mixture of opium alkaloids containing 50-95 weight% morphine, morphine hydrochloride, and apomorphine or other morphine derivs. are used practically as ~~homeopathic~~ preps. The combined administration of potentiated morphine and an addnl. potentiated ~~homeopathic~~ remedy, derived from the original habitual narcotic substance for which a patient has a pathol. craving, is suggested for periods of critical intoxication and abstinence.

ACCESSION NUMBER: 1998:572337 CAPLUS Full-text  
DOCUMENT NUMBER: 129:170539  
ORIGINAL REFERENCE NO.: 129:34512h,34513a  
TITLE: Method for the treatment of drug addiction and ~~homeopathic~~ remedy  
INVENTOR(S): Epshtein, Oleg Ilich  
PATENT ASSIGNEE(S): Russia  
SOURCE: PCT Int. Appl., 13 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Russian  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----
-----				
WO 9835680	A1	19980820	WO 1998-RU23	
19980209 <--				
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
DE, DK,				
EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ,				
LC, LK,				
LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT,				
RO, RU,				
SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK,				
ES, FI,				
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,				
CI, CM,				
GA, GN, ML, MR, NE, SN, TD, TG				
RU 2104006	C1	19980210	RU 1997-101895	
19970214 <--				
AU 9861264	A	19980908	AU 1998-61264	
19980209 <--				
PRIORITY APPLN. INFO.:			RU 1997-101895	A
19970214 <--				
			WO 1998-RU23	W
19980209 <--				
IPCI A61K0314-85 [ICM]				
IPCR A61K0031-485 [I,C*]; A61K0031-485 [I,A]; A61P0025-00 [I,C*];				

A61P0025-30

[I,A]

CC 1-11 (Pharmacology)

Section cross-reference(s): 4, 63

ST therapy drug addiction ~~homeopathic~~ opium alkaloid

IT Drug delivery systems

(~~homeopathic~~; method for treatment of drug addiction by  
~~homeopathic~~ preps. of opium alkaloids)

IT Alcoholism

Drug dependence

Drug withdrawal

(method for treatment of drug addiction by ~~homeopathic~~  
preps. of opium alkaloids)

IT Opioids

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic  
use); BIOL

(Biological study); USES (Uses)

(method for treatment of drug addiction by ~~homeopathic~~  
preps. of opium alkaloids)

IT 50-36-2, Cocaine 50-37-3, LSD 52-26-6, Morphine hydrochloride

57-27-2, Morphine, biological studies 58-00-4, Apomorphine

~~64-17-5~~, Ethanol, biological studies

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic  
use); BIOL

(Biological study); USES (Uses)

(method for treatment of drug addiction by ~~homeopathic~~  
preps. of opium alkaloids)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE

RE FORMAT

L13 ANSWER 30 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

AB The present invention relates mainly to a drug regimen involving  
ethanol amplified by diluting and shaking it many times according  
to a ~~homeopathic~~ method consisting in taking as a starting  
material Et alc. and diluting it in the ratio of 100/10000. The  
preferred embodiment consists in combining amplified ethanol and  
morphine, obtained by diluting and shaking them many times  
according to said ~~homeopathic~~ method, either from an opium  
alkaloid or morphine or a mixture of opium alkaloids with a mass  
of 65 to 95 % of morphine or from hydrochloride morphine diluted  
in the ratio of 200/1000.

ACCESSION NUMBER: 1998:542961 CAPLUS Full-text

DOCUMENT NUMBER: 129:166229

ORIGINAL REFERENCE NO.: 129:33705a,33708a

TITLE: Alcoholism treatment and ~~homeopathic~~  
pharmaceutical product

INVENTOR(S): Epshtein, Oleg Ilich

PATENT ASSIGNEE(S): Russia

SOURCE: PCT Int. Appl., 9 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833493	A1	19980806	WO 1998-RU17	
19980128 <--				
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RU 2103999	C1	19980210	RU 1997-101100	
19970131 <--				
AU 9861263	A	19980825	AU 1998-61263	
19980128 <--				
PRIORITY APPLN. INFO.:			RU 1997-101100	A
19970131 <--			WO 1998-RU17	W
19980128 <--				
IPCI A61K0031-045 [ICM,6]; A61K0031-485 [ICS,6]				
IPCR A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-485 [I,C*]; A61K0031-485				
[I,A]; A61P0025-00 [I,C*]; A61P0025-32 [I,A]				
CC 63-6 (Pharmaceuticals)				
Section cross-reference(s): 4				
ST homeopathy alcoholism treatment formulation				
IT Alcoholism				
(alcoholism treatment and homeopathic pharmaceutical product)				
IT Drug delivery systems				
(homeopathic; alcoholism treatment and homeopathic pharmaceutical product)				
IT 52-26-6, Morphine hydrochloride 64-17-5, Ethanol, biological studies				
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)				
(alcoholism treatment and homeopathic pharmaceutical product)				
REFERENCE COUNT: 4			THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS	
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				
L13 ANSWER 31 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN				
AB Title only translated.				
ACCESSION NUMBER: 1998:323561			CAPLUS Full-text	
DOCUMENT NUMBER: 128:299575				
ORIGINAL REFERENCE NO.: 128:59271a, 59274a				
TITLE: Homeopathic agent for recovery of psychophysiological homeostasis damaged by alcohol				

intake  
INVENTOR(S): Vorobeva, Tamara Mikhajlovna; Epshtejn, Oleg  
I.;  
Ilchikov, Mikhail Z.  
PATENT ASSIGNEE(S): Vorobeva, Tamara Mikhajlovna, Ukraine;  
Epshtejn, Oleg  
Ilich; Ilchikov, Mikhail Zakharovich  
SOURCE: Russ. From: Izobreteniya 1997, (35), 370.  
CODEN: RUXXE7  
DOCUMENT TYPE: Patent  
LANGUAGE: Russian  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2099052	C1	19971220	RU 1996-123975	
19961226 <--				
PRIORITY APPLN. INFO.:			RU 1996-123975	
19961226 <--				
IPCI A61K0031-045 [ICM,6]; A61K0009-08 [ICS,6] IPCR A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0009-08 [I,C*]; A61K0009-08 [I,A]; A61P0025-00 [I,C*]; A61P0025-32 [I,A] CC 63-6 (Pharmaceuticals) Section cross-reference(s): 4 ST homeopathic formulation alcoholism psychophysiol IT Alcoholism (Homeopathic agent for recovery of psychophysiol. homeostasis damaged by alc. intake) IT Drug delivery systems (homeopathic; Homeopathic agent for recovery of psychophysiol. homeostasis damaged by alc. intake) IT 64-17-5, Ethanol, biological studies RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (Homeopathic agent for recovery of psychophysiol. homeostasis damaged by alc. intake) OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD				

(1 CITINGS)

L13 ANSWER 32 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

AB The present invention relates to an agent for acting upon the organism and to biol. active substances. This invention more precisely relates to a potential preparation which is obtained by repeatedly cultivating and shaking a specific starting product having toxic properties and being poisonous to the organism (narcotics, alc., nicotine, industrial poisons, military poisonous substances). In order to cure alcoholism, this method uses ethanol as a starting substance during the potentialization, while it uses an opium alkaloid, morphine or morphine hydrochloride for curing drug problems. The potential agent of the present invention may be used in any medical homeopathic form and preferably together with the starting product.

ACCESSION NUMBER: 1998:219690 CAPLUS Full-text  
 DOCUMENT NUMBER: 128:279704  
 ORIGINAL REFERENCE NO.: 128:55292h,55293a  
 TITLE: Agent for acting upon the organism  
 INVENTOR(S): Epshtein, Oleg Iliich  
 PATENT ASSIGNEE(S): Epshtein, Oleg Iliich, Russia  
 SOURCE: PCT Int. Appl., 10 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Russian  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO. -----	KIND ----	DATE -----	APPLICATION NO. -----	DATE ----
WO 9814162 19970929 <--	A1	19980409	WO 1997-RU305	
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RU 2132181 19960930 <--	C1	19990627	RU 1996-118931	
AU 9747293 19970929 <--	A	19980424	AU 1997-47293	
PRIORITY APPLN. INFO.: 19960930 <--			RU 1996-118931	A
			WO 1997-RU305	W
19970929 <--				
IPCI A61J0003-00 [ICM,6]; A61K0031-045 [ICS,6]; A61K0031-485 [ICS,6]; A61K0035-78 [ICS,6] IPCR A61J0003-00 [I,C*]; A61J0003-00 [I,A]; A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-047 [I,A]; A61K0031-472 [I,C*]; A61K0031-472 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A]; A61K0036-00 [I,C*]; A61K0036-00 [I,A]; A61P0025-00 [I,C*]; A61P0025-30 [I,A]; A61P0025-32 [N,A]; A61P0025-34 [N,A]; A61P0025-36 [N,A] CC 4-7 (Toxicology) Section cross-reference(s): 1 IT 52-26-6, Morphine hydrochloride 57-27-2, Morphine, biological studies 64-17-5, Ethanol, biological studies RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				

(chemical and drug toxicity and the potential treatment)  
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE  
FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L13 ANSWER 33 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

AB Title only translated.

ACCESSION NUMBER: 1998:42854 CAPLUS Full-text

DOCUMENT NUMBER: 128:58520

ORIGINAL REFERENCE NO.: 128:11367a,11370a

TITLE: Homeopathic agent for alcohol dependence  
treatment

INVENTOR(S): Sergeev, Aleksej V.

PATENT ASSIGNEE(S): Russia

SOURCE: Russ. From: Izobreteniya 1997, (24), 232.

CODEN: RUXXE7

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----
RU 2088221	C1	19970827	RU 1996-100687	
19960110 <--				
PRIORITY APPLN. INFO.:			RU 1996-100687	
19960110 <--				
IPCI A61K0031-00 [ICM,6]; A61K0035-78 [ICS,6]				
IPCR A61K0036-71 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A];				
A61K0036-185				
[I,C*]; A61K0036-49 [I,A]; A61K0036-56 [I,A]; A61P0025-00 [I,C*];				
A61P0025-32 [I,A]				
CC 4-7 (Toxicology)				
Section cross-reference(s): 63				
ST alc dependence homeopathic				
IT Alcoholism				
Drug dependence				
Oak (Quercus)				
Ranunculus bulbosus				
Strychnos nux-vomica				
(homeopathic agent for alc. dependence treatment)				
IT 64-17-5, Ethanol, biological studies				
RL: ADV (Adverse effect, including toxicity); BIOL (Biological				
study)				
(homeopathic agent for alc. dependence treatment)				

L14 6 S L4 AND (?HOMEOPATH?)

L15 4 S L14 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN

AB Said invention is characterized by the application of a small and  
mini doses of an activated medical substance in the form of an  
agent for potentiating curing effects, i.e. enhancing action of  
the therapeutic dose of the same medical substance.



ACCESSION NUMBER: 2005:395147 CAPLUS Full-text  
 DOCUMENT NUMBER: 142:417235  
 TITLE: Agent for potentiating the therapeutic effects  
 of medicinal agents  
 INVENTOR(S): Epshtein, Oleg Iliich  
 PATENT ASSIGNEE(S): Russia  
 SOURCE: PCT Int. Appl., 20 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Russian  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039636	A1	20050506	WO 2004-RU374	
20040927 <--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
RU 2253478	C1	20050610	RU 2003-129126	
20031001 <--				
US 20070123518	A1	20070531	US 2006-574524	
20060331 <--				
PRIORITY APPLN. INFO.:			RU 2003-129126	A
20031001 <--			WO 2004-RU374	W
20040927				
IPCI A61K0045-00 [ICM,7]; A61J0003-00 [ICS,7]				
IPCR A61K0045-00 [I,A]; A61K0031-47 [I,C*]; A61K0031-47 [I,A]; A61K0031-485				
[I,C*]; A61K0031-485 [I,A]; A61K0031-551 [I,C*]; A61K0031-5513 [I,A];				
A61K0045-00 [I,C*]; A61K0045-06 [I,A]				
CC 63-6 (Pharmaceuticals)				
ST drug potentiation method anxiolytic homeopathy				
IT Drug delivery systems				

(homeopathic; agent for potentiating the therapeutic effects of medicinal agents)  
 IT 50-18-0, Cyclophosphane 50-23-7, Hydrocortisone 57-27-2, Morphine,  
 biological studies ~~439-14-5~~, Diazepam 12794-10-4, Benzodiazepine 51753-57-2, Phenazepam  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (agent for potentiating the therapeutic effects of medicinal agents)  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN

AB Method is disclosed for the treatment of chronic relapsing lip fissures and combinations of chronic relapsing lip fissures with exfoliative or atopic cheilitis. Method involves administration of proteolytic enzyme, application of an ointment of the complex composition on fissure and entire red border of the lips, administration of lidocaine blockade with premedication with apodiazepam at the dose of 5 mg by sublingual route, using ointment "Lorinden C", application of He-Ne laser treatment on damaged lip sites, administration of anti-histaminic preps., antiallergic diet and correction of psycho-emotional state. Treatment is carried out on the background of every day application of oral gels for lips protection and polyvitamins intake. Homeopathic ointment "Traumel" is prescribed for children instead of ointment "Lorinden C". Method ensures high effectiveness of treatment with the following absence of the relapses of the disease; neuro-dystrophic, inflammatory processes around lips and perioral skin are eliminated.

ACCESSION NUMBER: 2004:459069 CAPLUS Full-text  
 DOCUMENT NUMBER: 141:65131  
 TITLE: Method for the treatment of chronic relapsing lip  
 lip  
 lip  
 lip  
 lip  
 fissures and combinations of chronic relapsing lip  
 fissures with exfoliative or atopic cheilitis  
 INVENTOR(S): Brusenina, N. D.; Rybalkina, E. A.  
 PATENT ASSIGNEE(S): Moskovskii Gosudarstvennyi Mediko-Stomatologicheskii  
 Stomatologicheskii  
 Universitet, Russia  
 SOURCE: Russ., No pp. given  
 CODEN: RUXXE7  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Russian  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----
RU 2227017	C2	20040420	RU 2002-134786	
20021224 <--				
PRIORITY APPLN. INFO.:			RU 2002-134786	

20021224 <--  
 IPCI A61K0009-06 [ICM,7]; A61N0005-06 [ICS,7]; A61P0001-04 [ICS,7];  
 A61P0001-00  
     [ICS,7,C\*]  
 IPCR A61K0009-06 [I,C\*]; A61K0009-06 [I,A]; A61N0005-06 [I,C\*];  
 A61N0005-06  
     [I,A]; A61P0001-00 [I,C\*]; A61P0001-04 [I,A]  
 CC 1-12 (Pharmacology)  
     Section cross-reference(s): 2, 7, 8, 18, 63  
 ST lidocaine proteolytic enzyme sublingual apodiazepam Lorinden C lip  
     fissure; antidepressant antihistaminic antiallergic diet  
     homeopathic ointment Traumel laser  
 IT Drug delivery systems  
     (homeopathic, Traumel ointment; method for treatment of  
     chronic relapsing lip fissures and combinations of chronic  
 relapsing  
     lip fissures with exfoliative or atopic cheilitis)  
 IT Therapy  
     (homeopathy; method for treatment of chronic relapsing lip  
     fissures and combinations of chronic relapsing lip fissures  
 with  
     exfoliative or atopic cheilitis)  
 IT 137-58-6, Lidocaine 439-14-5, Apo-diazepam 9001-92-7,  
     Proteolytic enzyme  
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
     (Biological study); USES (Uses)  
     (method for treatment of chronic relapsing lip fissures and  
     combinations of chronic relapsing lip fissures with exfoliative  
 or  
     atopic cheilitis)  
  
 L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN  
 AB The inventive curative method for a pathol. syndrome consists in  
     inserting into an organism activated forms of minute antibody  
     doses which are produced by means of a repeated successive  
     dilution and an external action carried out on an antigen, e.g. a  
     substance or medicinal preparation influencing a mechanism forming  
     said pathol. syndrome. The inventive medicinal preparation for  
     curing the pathol. syndrome comprises an activated form of minute  
     doses of monoclonal, polyclonal or natural antibodies. Said  
     antibodies are produced by means of a repeated successive dilution  
     and an external action, preferably using homeopathic technol.,  
     which is carried out on an antigen, e.g. a substance or medicinal  
     preparation directly promoting the formation of the pathol.  
     syndrome or participating in regulating mechanisms for the  
     formation thereof. Activated forms of minute doses of antibodies  
     to the antigens of an exogenic and endogenic nature, autoantigens  
     and fetal antigens, are used. Anti-idiotypic antibodies are also  
     used.  
 ACCESSION NUMBER: 2001:935434 CAPLUS Full-text  
 DOCUMENT NUMBER: 136:58848  
 TITLE: Curative method for pathologic syndromes and  
         homeopathic medicinal preparations  
 INVENTOR(S): Epshtein, Oleg Ilich; Kolyadko, Tamara  
               Mikhailovna;  
               Shtark, Mark Borisovich  
 PATENT ASSIGNEE(S): Russia

SOURCE: PCT Int. Appl., 100 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Russian  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097842	A1	20011227	WO 2001-RU239	
20010619 <--				
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
RU 2181297	C2	20020420	RU 2000-115594	
20000620 <--				
CA 2413358	A1	20011227	CA 2001-2413358	
20010619 <--				
AU 2001069646	A	20020102	AU 2001-69646	
20010619 <--				
EP 1295606	A1	20030326	EP 2001-948169	
20010619 <--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030099636	A1	20030529	US 2002-311666	
20021217 <--				
US 20070224187	A1	20070927	US 2007-656226	
20070122 <--				
US 20080019982	A1	20080124	US 2007-656322	
20070122 <--				
US 20080050392	A1	20080228	US 2007-656217	
20070122 <--				
US 20080050360	A1	20080228	US 2007-656218	
20070122 <--				
US 20080131440	A1	20080605	US 2007-656216	
20070122 <--				
US 20100166762	A1	20100701	US 2010-701197	
20100205 <--				
PRIORITY APPLN. INFO.:			RU 2000-115594	A
20000620 <--				
			WO 2001-RU239	W
20010619 <--				
			US 2002-311666	A3
20021217 <--				

20070122

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IPCI A61K0039-395 [ICM,7]; A61P0037-00 [ICS,7]

IPCR A61K0039-395 [I,C\*]; A61K0039-395 [I,A]; A61P0037-00 [I,C\*];

A61P0037-00

[I,A]; C07K0016-00 [I,C\*]; C07K0016-00 [I,A]; C07K0016-18 [I,C\*];

C07K0016-24 [I,A]; C07K0016-26 [I,A]; C07K0016-44 [I,C\*];

C07K0016-44

[I,A]

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 15

ST antibody homeopathic formulation

IT Blood-group substances

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Rh, antibodies to; curative method for pathol. syndromes and  
homeopathic medicinal preps.)

IT Cannabinoids

Interferons

Prostaglandins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antibodies to; curative method for pathol. syndromes and  
homeopathic medicinal preps.)

IT Antibodies and Immunoglobulins

Antigens

Haptens

RL: PEP (Physical, engineering or chemical process); PYP (Physical  
process); THU (Therapeutic use); BIOL (Biological study); PROC

(Process);

USES (Uses)

(curative method for pathol. syndromes and homeopathic  
medicinal preps.)

IT Drug delivery systems

(homeopathic; curative method for pathol. syndromes and  
homeopathic medicinal preps.)

IT Antibodies and Immunoglobulins

RL: PEP (Physical, engineering or chemical process); PYP (Physical  
process); THU (Therapeutic use); BIOL (Biological study); PROC

(Process);

USES (Uses)

(monoclonal; curative method for pathol. syndromes and  
homeopathic medicinal preps.)IT 50-02-2 50-06-6, Phenobarbital, biological studies 50-23-7,  
Hydrocortisone 50-28-2, Estradiol, biological studies 50-35-1,  
Thalidomide 50-37-3, Lsd 50-48-6, Amitriptyline 50-49-7,

Imipramine

50-55-5, Reserpine 50-67-9, Serotonin, biological studies 50-  
78-2,Aspirin 51-41-2, Noradrenalin 51-45-6, Histamine, biological  
studies51-55-8, Atropine, biological studies 51-60-5, Proserine 51-  
61-6,Dopamine, biological studies 51-84-3, Acetylcholine, biological  
studies

52-53-9, Verapamil 52-86-8, Haloperidol 53-86-1, Indomethacin

54-11-5, Nicotine 54-31-9, Furosemide 54-85-3, Isoniazid 55-

63-0,

Nitroglycerin 56-40-6, Glycine, biological studies 56-84-8,  
 Aspartic acid, biological studies 56-86-0, Glutamic acid, biological  
 studies 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-  
 47-6,  
 Physostigmine 57-66-9, Probenecid 57-92-1, Streptomycin,  
 biological studies 58-08-2, Caffeine, biological studies 58-22-0,  
 Testosterone 58-55-9, Theophylline, biological studies 58-82-2, Bradykinin  
 58-93-5,  
 Hypothiazide 59-05-2, Methotrexate 59-26-7, Cordiamine 59-  
 43-8,  
 Thiamin, biological studies 59-66-5, Acetazolamide 59-67-6,  
 Nicotinic acid, biological studies 59-92-7, Levo-dopa, biological studies  
 60-99-1, Tisercin 64-39-1, Promedol 71-63-6, Digitoxin 71-  
 73-8,  
 Thiopental sodium 76-57-3, Codeine 77-10-1, Phencyclidine  
 86-54-4,  
 Aprestin 87-33-2, Nitrosorbide 92-84-2, Phenothiazine 97-77-  
 8,  
 Disulfiram 103-90-2, Paracetamol 137-58-6, Lidocaine 146-22-  
 5,  
 Nitrazepam 298-46-4, Tegretol 299-42-3, Ephedrine 318-98-9,  
 Anapriline 364-62-5, Metoclopramide 437-38-7, Fentanil  
 439-14-5, Diazepam 443-48-1, Metronidazole 465-65-6, Naloxone  
 511-12-6, Dihydroergotamine 586-06-1, Orciprenaline 621-72-7,  
 Dibazol 835-31-4, Naphthizine 982-43-4, Libexin 985-12-6, No-spa  
 1069-66-5,  
 Depakin 1078-21-3, Phenibut 1134-47-0, Baclofen 1406-16-2,  
 Vitamin d 1406-18-4, Vitamin e 1490-04-6, Menthol 1972-08-3,  
 Tetrahydrocannabinol 2898-12-6, Mezapam 3644-61-9, Midocalm  
 3737-09-5, Ritmilin 3930-20-9, Sotalol 4205-91-8, Clofelin  
 5786-21-0, Azaleptine 6740-88-1, Ketamine 6893-02-3,  
 Triiodothyronine 7085-55-4, Troxerutin 7491-74-9, Nootropil 9002-72-6,  
 Somatotropin 9004-10-8, Insulin, biological studies 9005-49-6, Heparin,  
 biological studies 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological  
 studies 9015-82-1, Angiotensin-converting enzyme 9015-94-5, Renin,  
 biological studies 9025-82-5, Phosphodiesterase 9035-34-1, Cytochrome a  
 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11128-99-7,  
 Angiotensin ii 12656-61-0, Cerebrolysin 13292-46-1, Rifampicin 13311-84-7,  
 Flutamide 13392-18-2, Fenoterol 14286-84-1, Halidor 14402-89-2, Sodium  
 nitroprusside 14611-51-9, Selegiline 14769-73-4, Levamisol  
 14838-15-4, Norephedrine 14976-57-9, Tavegil 15307-86-5,  
 Diclofenac 15663-27-1, Cisplatin 15687-27-1, Ibuprofen 15876-67-2,

Ubretid  
 16110-51-3, Cromolyn 16773-42-5, Ornidazole 17479-19-5,  
 Dihydroergocristine 18559-94-9, Salbutamol 19216-56-9,  
 Prazosin  
 19774-82-4, Cordarone 20830-75-5, Digoxin 22254-24-6, Atrovent  
 23214-92-8, Doxorubicin 23288-49-5, Probucol 23476-83-7,  
 Prospidine  
 25614-03-3, Bromocryptine 25717-80-0, Molsidomine 27236-88-0,  
 Sodium  
 hydroxybutyrate 28797-61-7, Pirenzepine 29122-68-7, Atenolol  
 31637-97-5, Etofibrate 34262-84-5 34580-13-7, Ketotifen  
 34580-14-8,  
 Zaditen 36282-47-0, Tramal 36894-69-6 39391-18-9,  
 Cyclooxygenase  
 42399-41-7, Diltiazem 42408-82-2, Butorphanol 51753-57-2,  
 Phenazepam  
 54063-53-5, Propafenone 54739-18-3, Fluvoxamine 54910-89-3,  
 Fluoxetine  
 55142-85-3, Ticlopidine 57808-66-9, Motilium 59122-46-2,  
 Misoprostol  
 59467-70-8, Midazolam 62571-86-2, Captopril 62683-29-8, Colony  
 stimulating factor 66357-35-5, Ranitidine 66829-00-3,  
 Aminalone  
 71320-77-9, Moclobemide 72841-18-0, Cytochrome a3 73590-58-6,  
 Omeprazole 75438-57-2, Moxonidine 75847-73-3, Enalapril  
 76824-35-6,  
 Famotidine 79617-96-2, Sertraline 79794-75-5, Loratadine  
 80214-83-1,  
 Rulid 81093-37-0, Pravastatin 82626-48-0, Zolpidem 84057-84-  
 1,  
 Lamotrigine 85721-33-1, Ciprofloxacin 88040-23-7, Tsefepim  
 96829-58-2, Orlistat 103628-46-2, Sumatriptan 106266-06-2,  
 Risperidone  
 106463-17-6, Omnic 110942-02-4, Aldesleukin 111470-99-6,  
 Norvasc  
 121181-53-1, Filgrastim 124750-99-8, Cozaar 142805-56-9,  
 Topoisomerase  
 ii 214692-62-3, Omez 383123-63-5, Detralex  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (antibodies to; curative method for pathol. syndromes and  
 homeopathic medicinal preps.)  
 OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE  
 THIS RECORD  
 (6 CITINGS)  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE  
 FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE  
 RE FORMAT

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN

AB An analgesic, antipyretic, anti-inflammatory, anti-influenzal  
 preparation is disclosed which comprises (parts by weight) aspirin  
 10-500, paracetamol or ascorbic acid 10-500, caffeine 1-50,  
 diazepam 1-50 or amitryptiline 1-20 or thioridazine 1-20, or  
 hydroxyzine 1-20 or promethazine 1-30, or a mixture of 1-50 parts  
 phenylpropanolamine and 1-50 parts chlorpheniramine or a mixture  
 of 10-5000 parts propyphenazone and 1-50 parts codeine and a

mixture of 1-50 parts homeopathic prepns. of Aconitum, Gelsemium, Eupatorium, Echinacea, Bryonia, or a mixture of 0.01-10 parts homeopathic prepns. of white arsenic, Hydrastis, Phytolacca, Medorrhinum, Mezereum, iron phosphate, Influenzium, phosphorus triiodate, Sambucus, and pharmaceutically acceptable excipients.

The preparation may be formed into tablets or capsules.

ACCESSION NUMBER: 2001:189220 CAPLUS Full-text  
DOCUMENT NUMBER: 134:212698  
TITLE: Analgesic, antipyretic, anti-inflammatory, flu-preventing medicine  
INVENTOR(S): Dobrescu, Dumitru  
PATENT ASSIGNEE(S): Rom.  
SOURCE: Rom., 3 pp.  
CODEN: RUXXA3  
DOCUMENT TYPE: Patent  
LANGUAGE: Romanian  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 113712	B3	19981030	RO 1996-353	
19960222 <--				
PRIORITY APPLN. INFO.:			RO 1996-353	
19960222 <--				
IPCI A61K0009-28 [ICM,6]				
IPCR A61K0009-28 [I,C*]; A61K0009-28 [I,A]				
CC 63-6 (Pharmaceuticals)				
IT Drug delivery systems				
(homeopathic; analgesic, antipyretic, anti-inflammatory, flu-preventing formulation)				
IT 50-48-6 50-52-2, Thioridazine		50-78-2, Aspirin	50-81-7,	
Ascorbic acid, biological studies		58-08-2, Caffeine, biological studies		
60-87-7, Promethazine		68-88-2, Hydroxyzine	76-57-3, Codeine	
103-90-2, Paracetamol		113-92-8, Chlorpheniramine	439-14-5,	
Diazepam		479-92-5, Propyphenazone	14838-15-4,	
Phenylpropanolamine				
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (analgesic, antipyretic, anti-inflammatory, flu-preventing formulation)				

L16 5 S L5 AND (?HOMEOPATH?)  
L17 4 S L16 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
L18 2 S L17 NOT L15  
L19 4 S L6 AND (?HOMEOPATH?)  
L20 3 S L19 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
L21 2 S L20 NOT L15  
L22 2 S L21 NOT L18

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

AB Expts. on animals with transplanted tumors (Lewis lung carcinoma and carcinosarcoma Walker-256) showed that combination treatment



with cyclophosphane and its ~~homeopathically~~ potentiated forms  
increases antitumoral activity of the preparation

ACCESSION NUMBER: 2003:542972 CAPLUS Full-text  
DOCUMENT NUMBER: 141:64483  
TITLE: Potentiated cyclophosphane: Experimental study  
of the effect on tumor development and efficiency of  
cytostatic therapy

AUTHOR(S): Amosova, E. N.; Zueva, E. P.; Razina, T. G.;  
Krylova,  
S. G.; Shilova, N. V.; Epstein, O. I.  
CORPORATE SOURCE: Tomsk Research Center, Institute of  
Pharmacology,  
Siberian Division of the Russian Academy of  
Medical Sciences, Tomsk, Russia  
SOURCE: Bulletin of Experimental Biology and Medicine  
(Biologii i Meditsiny) (2003), 135-136 (Suppl. 1),  
107-110  
CODEN: BEXBAN; ISSN: 0007-4888  
PUBLISHER: Kluwer Academic/Consultants Bureau  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
CC 1-6 (Pharmacology)  
ST cyclophosphane potentiated ~~homeopathic~~ bipathic antitumor  
cytostatic lunch carcinoma  
IT Therapy  
(homeopathy; effect of potentiated cyclophosphane on tumor  
development and efficiency of cytostatic therapy)  
IT 50-18-0, Cyclophosphane  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(effect of potentiated cyclophosphane on tumor development and  
efficiency of cytostatic therapy)  
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE  
FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE  
RE FORMAT

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN  
AB Antibodies to cyclophosphamide obtained by ~~homeopathic~~  
potentiation and administered in ultralow doses exhibit no  
antitumoral activity and did not modulate the effectiveness of  
cyclophosphamide during antitumor therapy of animals with  
transplanted tumors (Lewis lung carcinoma and Ehrlich  
adenocarcinoma).

ACCESSION NUMBER: 2003:542932 CAPLUS Full-text  
DOCUMENT NUMBER: 140:302022  
TITLE: Effect of Potentiated Antibodies to  
Cyclophosphamide  
on the Development of Tumors and Effectiveness  
of Cytostatic Therapy under Experimental  
Conditions  
AUTHOR(S): Amosova, E. N.; Zueva, E. P.; Razina, T. G.;

Krylova,  
CORPORATE SOURCE: S. G.; Shilova, N. V.; Epstein, O. I.  
Pharmacology, Tomsk Research Center, Institute of  
Medical Siberian Division of the Russian Academy of  
Sciences, Moscow, Russia  
SOURCE: Bulletin of Experimental Biology and Medicine  
Biologii i (Translation of Byulleten Eksperimental'noi  
Meditsiny) (2003), 135-136(Suppl. 1), 54-56  
CODEN: BEXBAN; ISSN: 0007-4888  
PUBLISHER: Kluwer Academic/Consultants Bureau  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
CC 15-3 (Immunochemistry)  
Section cross-reference(s): 1  
IT 50-18-0, Cyclophosphamide  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(effect of potentiated antibodies to cyclophosphamide on the  
development of tumors and effectiveness of cytostatic therapy  
under exptl. conditions)

L23 3 S L7 AND (?HOMEOPATH?)  
L24 2 S L23 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
L25 0 S L24 NOT L15